39 related articles for article (PubMed ID: 12409642)
1. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.
Ross JS; Fletcher JA; Linette GP; Stec J; Clark E; Ayers M; Symmans WF; Pusztai L; Bloom KJ
Oncologist; 2003; 8(4):307-25. PubMed ID: 12897328
[TBL] [Abstract][Full Text] [Related]
2. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.
Ross JS; Fletcher JA
Oncologist; 1998; 3(4):237-252. PubMed ID: 10388110
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapeutic options and future perspectives for HER2-positive breast cancer.
Wang J; Xu B
Signal Transduct Target Ther; 2019; 4():34. PubMed ID: 31637013
[TBL] [Abstract][Full Text] [Related]
4. TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer.
Majidzadeh-A K; Esmaeili R; Abdoli N
BMC Res Notes; 2011 Jun; 4():215. PubMed ID: 21702980
[TBL] [Abstract][Full Text] [Related]
5. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
[TBL] [Abstract][Full Text] [Related]
6. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
7. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
8. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) gene amplification of breast cancer in Indian women.
Singhai R; Patil V; Patil A
Asian Pac J Cancer Prev; 2011; 12(1):179-83. PubMed ID: 21517254
[TBL] [Abstract][Full Text] [Related]
10. Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?
Yaziji H; Gown AM
Adv Anat Pathol; 2002 Nov; 9(6):338-44. PubMed ID: 12409642
[TBL] [Abstract][Full Text] [Related]
11. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
